Plain-English translation of NCT06863805 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are studying whether a new type of blood test—called a liquid biopsy—can help doctors choose the right treatment for advanced thyroid cancer. Instead of relying only on tissue samples from surgery or biopsy, this study compares what doctors learn from blood tests against traditional tumor tissue analysis to see if blood tests give equally useful information about your cancer's genetic makeup.
Currently, doctors must often rely on tumor tissue samples to understand which treatments will work best, but these samples aren't always available or adequate. This study explores whether blood tests could become a faster, easier, non-invasive way to identify which patients will respond to treatment and to detect when cancer begins resisting a drug—helping doctors switch strategies sooner.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will have blood drawn so researchers can perform a liquid biopsy—a non-invasive test that analyzes cancer-related material circulating in your blood. This blood sample will be compared against your tumor tissue genetic analysis to see how well the blood test reflects your cancer's biology. The study involves a single blood draw at one hospital center in Bologna, Italy, with a small group of about 10 patients total.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Italy
Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Enrollment target
~10 participants
Started
December 2022
Primary completion
December 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in March 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Margherita Nannini
Ospedale S. Orsola-Malpighi
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.